Molecular Diagnostics in Infectious Disease Sector Projects Significant Growth and Technological Advances from 2024-2028

Dublin, March 12, 2024 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With Analysis and Executive Guides 2024 - 2028" report has been added to * ResearchAndMarkets.com's* offering.

The *latest research publication on Molecular Diagnostics for Infectious Diseases* delves into the market's anticipated expansion and the technological innovations forecasted to drive the industry forward between 2024 and 2028. This insightful analysis offers a comprehensive view into the burgeoning field, where nucleic acid testing is positioned to become a cornerstone in the fight against infectious diseases.

Syndromic testing developments and multiplex technologies are paramount in shaping the direction of the market. The industry is undergoing a transformational shift, leveraging advancements in biotechnology and genomics, which is propelling the growth and valuation of companies in this space. As molecular diagnostics becomes increasingly critical in healthcare, stakeholders are keen to understand the intricate dynamics and trends that are promoting this market development.

An exciting facet of this transformation includes the balance between nucleic acid testing and immunoassay approaches, with innovations suggesting a bright future for diagnostic leads in combating infectious diseases. The comprehensive analysis presents not only technological forecasts but also potential impacts on the global persistence of antimicrobial drug resistance.

The in-depth report encompasses key data, including detailed country and regional market breakouts, and situates the United States within the wider context, offering valuable insights into Medicare Fee Payment Schedules. It emphasizes the global appeal and significance of its findings.

Clinicians, industry executives, and investors will find the contents of the report invaluable in forming strategies to navigate and capitalize on the expected market growth. With extensive coverage of over 15 individual countries and 4 major regions, the report is designed to serve as a pivotal guide for those operating or investing in the Molecular Diagnostics for Infectious Diseases sector.

The ever-evolving nature of the molecular diagnostics market for infectious diseases invites a promising outlook for disease control and even eradication. The report provides accessible intelligence that empowers stakeholders to make informed decisions and stay at the forefront of this exciting and dynamic industry.

*Key Topics Covered*

1. Market Guides
2. Introduction and Market Definition
3. The Infectious Diseases - Market Analysis by Disease
4. Industry Overview
5. Profiles of Key MDx Companies
6. Market Trends
7. Molecular Dx - Infectious Disease Recent Developments
8. The Global Market for Molecular Diagnostics Infectious Disease
9. Global MDx Infectious Disease Markets - By Syndrome
10. Global MDx Markets for Infectious Disease - by Plex
11. Global MDx Infectious Disease Markets - by Place
12. Appendices

*Companies Mentioned*

· 1928 Diagnostics
· Abacus Diagnostica
· Abbott Laboratories
· Accelerate Diagnostics
· Access Bio
· Ador Diagnostics
· ADT Biotech
· Akonni Biosystems
· Altona Diagnostics
· Alveo Technologies
· Anatolia Geneworks
· Anitoa
· Antelope Dx
· Applied BioCode
· Assurance Scientific Laboratories
· Aureum Diagnostics
· Aus Diagnostics
· Beckman Coulter Diagnostics
· Becton, Dickinson and Company
· Binx Health
· Bio-Rad Laboratories, Inc
· Biocartis
· BioFire Diagnostics (bioMérieux)
· bioMérieux Diagnostics
· Bosch Healthcare Solutions GmbH
· Celemics
· Cepheid (Danaher)
· Chembio
· Co Diagnostics
· Credo Diagnostics Biomedical
· Cue Health
· Curetis N.V. / Curetis GmbH
· Detect
· Diagenode Diagnostics
· Diascopic
· Diasorin S.p.A.
· Domus Diagnostics
· Eiken Chemical
· Element Biosciences
· Enzo Biochem
· Eurofins Scientific
· Fluxergy
· Fulgent Genetics
· Fusion Genomics.
· Genedrive
· Genetic Signatures
· GenMark Dx (Roche)
· Genomadix
· Grifols
· Grip Molecular Technologies
· Hibergene Diagnostics
· Hologic
· Illumina
· Immunexpress
· Inflammatix
· Invetech
· Janssen Diagnostics
· Karius
· Lexagene
· LightDeck Diagnostics
· Lucira Health
· Luminex Corp (DiaSorin)
· LumiraDx
· Lumos Diagnostics
· Mammoth Biosciences
· Maxim Biomedical
· Meridian Bioscience
· Mesa Biotech (Thermo Fisher)
· MicroGem
· Millipore Sigma
· Mindray
· Minute Molecular
· Mobidiag (Hologic)
· Molbio Diagnostics
· NanoDx
· Nanomix
· Novacyt
· Novel Microdevices
· OnsiteGene
· Operon
· Oxford Nanopore Technologies
· Panagene
· Pathogenomix
· Perkin Elmer
· Prenetics
· Primerdesign (Novacyt)
· Prominex
· Proof Diagnostics
· Qiagen
· QuantuMDx
· Quest Diagnostics
· QuidelOrtho
· Randox Toxicology
· Roche Molecular Diagnostics
· Saw Diagnostics
· Scope Fluidics
· SD Biosensor
· Seegene
· Siemens Healthineers
· Singular Genomics
· SomaLogic
· Sona Nanotech
· SpeeDx
· T2 Biosystems
· Talis Biomedical
· Thermo Fisher Scientific Inc.
· Ultima Genomics
· Vela Diagnostics
· Veramarx
· Veredus Laboratories
· Vircell
· Vir
· Visby Medical
· XCR Diagnostics
· YD Diagnostics
· Zhejiang Orient Gene Biotech

For more information about this report visit https://www.researchandmarkets.com/r/huh9jr

*About ResearchAndMarkets.com*
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900